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Abstract 
Analysis of the brain specific biomarkers amyloid β42 (Aβ42) and total tau (t-tau) protein in 
cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for 
differentiating Alzheimer’s Disease (AD) from non-demented controls. International 
guidelines are contradictory in their advice on the use of CSF biomarkers in AD 
diagnostics, resulting in a lack of consistency in clinical practice. We present three case 
reports that illustrate clinical practice according to the Dutch and European guidelines 
and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard 
diagnostic workup for AD. 
 
Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by 
the accumulation of extracellular senile plaques and intracellular neurofibrillary tangles. It 
is becoming increasingly important to accurately diagnose AD at an early stage. An 
adequate diagnosis allows appropriate education, guidance, care and treatment for 
patients and their informal caregivers. Occupational therapy and caregiver support 
improve quality of life for AD patients, while treatment with acetylcholinesterase 
inhibitors can improve cognitive function [1]. Moreover, potentially neuroprotective  
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therapies for AD, which are currently under development, are probably most beneficial 
when initiated at an early stage of the disease [2]. 
According to the current NINCDS-ADRDA diagnostic guidelines [3], definite 
diagnosis of AD can only be made post-mortem by histopathological examination of the 
brain. However, by using different diagnostic tools, such as neuropsychological tests and 
imaging techniques, a probable diagnosis can be achieved with reasonable sensitivity and 
specificity. Nowadays, analysis of cerebrospinal fluid (CSF) biomarkers amyloid β42 
(Aβ42), total tau (t-tau) and phosphorylated tau (p-tau) is increasingly used to differentiate 
AD from other dementia disorders and non-demented patients. AD patients show a 
typical pattern of decreased Aβ42 and increased p-tau and t-tau. The combination of 
decreased Aβ42 and increased t-tau has a sensitivity and specificity of more than 85% in 
differentiating AD from healthy controls [4, 5]. The addition of p-tau to Aβ42 and t-tau 
further increases specificity for AD [4]. Moreover, analysis of CSF biomarkers resulted in 
a correct diagnosis in 82% of neuropathologically confirmed AD and non-AD cases [6]. A 
high negative protective value (NPV) of 96% shows that normal CSF results make AD 
pathology very unlikely [7]. For differentiating AD from vascular dementia (VaD), both 
the ratio of Aβ42/p-tau, and t-tau × p-tau/Aβ42 yield sensitivities and specificities of more 
than 85% [8–10]. When CSF biomarkers are used to differentiate AD from dementia 
syndromes such as frontotemporal dementia (FTD) and dementia with Lewy bodies 
(DLB), discrimination is more difficult. FTD can be discriminated from AD with 
reasonable sensitivity and specificity, using the t-tau/Aβ42 ratio, and especially using p-
tau, which is not elevated in FTD [11–14]. DLB patients show normal p-tau levels and 
lower tau levels compared to AD patients but overlap of values is still high, probably due 
to mixed pathology in the DLB group [15, 16].  
The prevailing guidelines, NINCDS-ADRDA and the DSM-IV-TR, do not include CSF 
biomarkers in AD diagnostics, since the criteria were developed before these biomarkers 
were described [3]. The dementia guidelines from the American Academy of Neurology, 
which were last revised in 2001, mention CSF biomarkers but state that they are not 
appropriate for routine use in clinical practice [17]. The more recent European 
Federation of Neurological Societies (EFNS) dementia guidelines (2006) state that ‘CSF 
Aβ42, t-tau, and p-tau can be used as an adjunct in cases of diagnostic doubt’ [18]. Dutch 
guidelines state that CSF analysis of these biomarkers are not part of the standard 
diagnostic workup but can be taken into consideration when a higher diagnostic certainty 
is desired [19, 20]. More specifically, they state that CSF analysis can be of additional 
value in patients under 65 years of age whose differential diagnosis is broad, or in patients 
in whom imaging techniques and neuropsychological tests do not lead to a clear-cut 
diagnosis. In 2007, a proposition was made for revising the research criteria for the 
diagnosis of AD [21]. This proposition states that a probable diagnosis of AD should be 
made using the core diagnostic criteria of early subjective memory impairment which 
gradually progresses over more than 6 months, with objective evidence of significant 
memory impairment deficits supported by at least 1 of 3 abnormal biomarker values, i.e. 
abnormal CSF biomarkers, abnormal PET/SPECT scanning, or abnormal MRI, the latter 
2 with the hallmarks of mediotemporal lobe hypoperfusion or atrophy. The somewhat 
contradictory suggestions in the guidelines result in inconsistency of routine diagnostics 
in clinical practice. We aim to clarify the contribution of CSF biomarkers in clinical 
practice with 3 typical case reports, and illustrate the need for an unambiguous guideline. 
At the Radboud University Nijmegen Medical Centre (RUNMC) memory clinic we 
currently use CSF analysis according to the latest Dutch and European guidelines. The 
reference values for the age group over 50 years that we established in our own laboratory  
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using the sandwich ELISAs by Innogenetics are: Aβ42 >500 ng/l, t-tau <350 ng/l, p-tau <85 
ng/l [8, 22]. These values are largely in line with the reference values proposed in previous 
publications [5, 7]. In the last 1.5 years, CSF analysis was performed in approximately 30 
patients of the 200 patients that we saw at our memory clinic. The following case reports 
were selected from this patient group to exemplify the value of biomarker analysis in the 
standard diagnostic workup for AD.  
Case Reports 
Patient A is a 67-year-old woman, who had complaints about short-term memory loss. Her relatives 
noticed her repeatedly asking the same questions. She had become insecure and started to double-check 
her own actions. A friend had to help her with administrative duties. Her complaints developed 
gradually over the last 1.5 years. She had a history of hypertension and osteoporosis. She smoked 20 
cigarettes a day from the age of 15. Neuropsychological tests indicated significant cognitive decline, with 
a Mini Mental State Examination (MMSE) [23] score of 22 out of 30, and a Cambridge Cognitive 
Examination (CAMCOG, a section of the CAMDEX) [24] score of 81 out of 104 (a higher score 
indicates a better performance; cut-off adjusted for age and education is 83). Mainly semantic memory 
function, both verbally and visually, recognition and orientation in time and place were affected, while 
visuoconstruction, attention, executive functioning and cognitive speed were normal. Therefore, AD 
was suspected rather than VaD. The subsequent MRI showed extensive white matter lesions (<25% of 
white matter), probably of vascular-ischemic origin, next to distinct atrophy with broadening of the 
ventricles, and hippocampal atrophy grade 1 according to Scheltens et al.’s rating scale [25]. Because of 
these MRI results and the patient’s vascular risk factors, a diagnosis of possible VaD was considered 
next to AD. A lumbar puncture and further neuropsychological testing was performed to help clarify 
the diagnosis. The CSF biomarker levels were: Aβ42 424 ng/l, t-tau 634 ng/l and p-tau 117 ng/l. The 
decreased level of Aβ42 with a significantly elevated t-tau and p-tau and, consequently, an Aβ42/p-tau 
ratio of 3.6, which is far below the cut-off ratio of 11.0 to discriminate VaD from AD, supported the 
diagnosis of AD over VaD, and therefore we diagnosed probable AD with cerebrovascular morbidity 
[8]. Treatment with acetylcholinesterase inhibitors was initiated, which she tolerated well. 17 months 
after diagnosis the patient was stable without further deterioration in cognition, behavior or daily 
activities and no further vascular disease hallmarks developed, supporting our initial diagnosis. 
Patient B is a 63-year-old woman who was referred to our clinic for a second opinion. The past 2 
years she had become increasingly anxious about new situations. She was having difficulty finding 
words and engaging in conversations. In 2007, a neurologist could not identify a cognitive disorder. At 
that time, she was diagnosed as having a dysthymic disorder and post-traumatic stress disorder by a 
psychiatrist and was treated with venlafaxine 75 mg once daily. However, when she came to our 
memory clinic 9 months later, her complaints had not disappeared. She still had difficulty engaging in 
conversations and could not finish her chores because she kept forgetting what she was doing. Due to 
anxiety she stopped driving, internet banking and using the phone and video recorder, and there was a 
severe loss of initiative. She had a MMSE score of 21 out of 30, a CAMCOG score of 68 out of 104 (cut-
off adjusted for age and education is 83) and a geriatric depression scale (GDS) score of 2 out of 15 (a 
score above 7 indicates depression) [26]. These results suggested cognitive decline, possibly AD, since 
no other underlying disease was apparent, and history taking and GDS score showed that her depressive 
mood was in remission. The MRI, already made in 2007, was re-evaluated and showed asymmetrical 
frontotemporal atrophy without medial temporal lobe atrophy (fig. 1). A lumbar puncture was 
performed, because the neuropsychological assessment and the MRI were not fully conclusive and still 
left the possibility of AD diagnosis. CSF analysis showed normal levels of all biomarkers (Aβ42 560 ng/l, 
t-tau 335 ng/l and p-tau 77 ng/l). These results made an AD diagnosis less likely and could be 
compatible with a diagnosis of FTD. Further specific neuropsychological testing was done, which 
showed below average learning curves with unimpaired delayed recall and recognition, decline in 
attention and executive functions with reduced information processing speed and apathy. Apart from a 
below-average word fluency, there were no language disorders. The combination of MRI, CSF 
biomarker results and neuropsychological examination added to the likelihood of FTD. 15 months later 
the patient had deteriorated mildly with an MMSE now of 18 out of 30. No behavioral problems had 
occurred and her mood was stable. This clinical follow-up still leaves room for AD. 
Patient C is a 65-year-old woman who visited our memory clinic with gradually increasing memory 
problems over the past 3 years. Her medical history revealed a subarachnoidal hemorrhage at the age of 
33 due to an aneurysm of the anterior communicating artery, and excision of a frontal meningioma at  
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the age of 54. After examination, we objectified both verbal and visual memory dysfunction and 
disturbances in language, attention, visuoconstruction and executive functions, which influenced her 
daily activities. Her MMSE score was 21 out of 30 with a CAMCOG score of 80 out of 104 (cut-off 
adjusted for age and education is 83). We suspected a diagnosis of AD, but because of a complicated 
history and young age, we wanted to support this diagnosis with biomarker evidence. An MRI could not 
be performed because the patient had a metal clip on the cerebral aneurysm. A CT-scan showed left-
sided frontal atrophy and frontobasal atrophy of both hemispheres. CSF analysis was done, showing an 
Aβ42 concentration of 431 ng/l, a t-tau concentration of 545 ng/l and a p-tau concentration of 118 ng/l. 
The decreased level of Aβ42 and elevated t-tau and p-tau confirmed our notion of the diagnosis as 
possible AD. Treatment with cholinesterase inhibitors was initiated. After 16 months, mild 
deterioration in memory function was seen, compatible with the diagnosis of AD. 
Discussion 
These case reports illustrate that CSF analysis may be a valuable addition to the 
standard workup for AD, when used according to the latest Dutch diagnosis guidelines 
and the Dubois criteria for Alzheimer type pathology, although the latter are proposed as 
research criteria and await further validation [19, 21]. These cases underline that in 
current clinical practice we already frequently refer to these AD research criteria, relying 
on positive AD-hallmarks, instead of the classical NINCDS-ADRDA criteria that only 
warrant AD diagnosis by exclusion of other systemic or brain diseases. 
The first case shows the affirmative value of CSF biomarkers, when the combination of 
Aβ42 and p-tau indicates that a diagnosis of AD with vascular disease is more likely than 
VaD. The second case report displays the use of CSF biomarkers when the differential 
diagnosis is broader. In addition, more diagnostic certainty was desired because the 
patient came for re-evaluation, and MRI had not led to a clear-cut diagnosis. The third 
case shows an example of a patient group in which MRI cannot be performed. Other 
conditions that exclude MRI scanning include having a cardiac pacemaker or 
claustrophobia. As an alternative a CT-scan can be performed to search for white matter 
lesions and to exclude a tumor, but the diagnostic value of CT-images is limited by the 
lower resolution and lower sensitivity for vascular lesions. Moreover, visualization of the 
temporal horn requires additional reconstruction, and CT more often leads to scatter 
artifacts. Therefore, CSF analysis is regarded as a better alternative, when a lumbar 
puncture is not contra-indicated, e.g. in case of structural lesions. 
The latest guidelines state that CSF analysis can be valuable in AD diagnostic workup 
only as an add-on diagnostic tool [21]. In certain cases, the CSF biomarkers can be of help 
in the differential diagnosis, both for confirming and excluding a diagnosis of AD. Due to 
practical and occasionally medical circumstances, CSF analysis is not suitable to be used 
as a primary diagnostic tool for all patients investigated at a memory clinic. However, 
neither the invasiveness of lumbar puncture nor post-puncture complaints are any longer 
a serious concern with modern techniques, especially in older patients. In a large series 
with over 2,000 patients zero complications have occurred, and the percentage of older 
patients suffering from post-lumbar-puncture pain is low, ranging from 0.9% to 4.1% 
[27–29]. 
It might be argued that CSF analysis is limited by the high inter-laboratory coefficient 
of variation [30, 31]. Even though processing and storage conditions have been 
standardized, inter-laboratory and intra-laboratory variation is still considerable [32]. 
However, once reference values have been established within the same laboratory, test 
results can be compared and reproduced. In a previously performed retrospective 
diagnostic validation study of Aβ42, t-tau and p-tau in dementia we calculated optimal  
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cut-offs for our population [33], because applying previously published criteria resulted in 
less optimal test results, e.g. for the Hansson criteria a sensitivity of 69% and a specificity 
of 61% [7]. Using these reference values we can reliably generate CSF biomarker values 
with a sensitivity of 96% and a specificity of 97%, and draw firm conclusions from them 
[22]. 
So far, all CSF biomarkers studies have been carried out in selected patient cohorts as 
part of retrospective case control studies or in expert referral clinics, and predetermined 
cut-off values were usually not applied. Prospective studies should further demonstrate 
the discriminative value of CSF analysis in clinical practice. An example is a recent study 
showing the prognostic value of CSF biomarkers in patients with mild cognitive 
impairment [34]. We feel that, in spite of its limitations, CSF analysis already is a valuable 
add-on diagnostic measure, as illustrated by these case reports, in which predetermined 
cut-offs were used. The prevailing guidelines, therefore, should be updated to ensure 
consensus on the CSF application in clinical practice. 
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